Jagsonpal Q2 and H1 FY27: consolidated revenue rises 29%
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal reported Q2 FY27 consolidated revenue of Rs 964 million, up 29%, after Aequitas consolidation. Standalone Q2 revenue rose 9.3% to Rs 814 million, EBITDA was Rs 185 million at a 22.7% margin and profit after tax was Rs 126 million. H1 revenue reached Rs 1,636 million, up 9%, while EBITDA and profit rose 11.3% and 10.3% to Rs 375 million and Rs 258 million. Cash was Rs 1,347 million. The Group Pharma wellness deal closed on October 1. Management expects Q3 revenue above Rs 1 billion and Rs 5 billion by FY28.
Positive overall: acquisitions and core growth support expansion, but Q2 margin pressure and integration costs are near-term risks for investors.